Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2016-08-17 Regulatory Filings
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Medivir licenses rights to MIV-802 to Trek Therapeutics
Regulatory Filings Classification · 99% confidence The document is a press release announcing a licensing agreement between Medivir and Trek Therapeutics for the drug MIV-802, which involves milestone payments and royalties. This type of corporate action, specifically related to licensing intellectual property and future revenue streams, falls under financing or capital structure changes, although it is not a direct issuance of equity or debt. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate fit as it concerns the monetization and development funding structure of an asset. It is not an Earnings Release (ER), Interim Report (IR), or a standard regulatory filing like 10-K. Since it details a significant transaction affecting future financial rights, CAP is selected over the general 'RNS' fallback.
2016-08-17 English
Medivir utlicensierar rättigheterna för MIV-802 till Trek Therapeutics
Capital/Financing Update Classification · 95% confidence The document describes a licensing agreement between Medivir AB and Trek Therapeutics regarding the drug MIV-802 for Hepatitis C treatment. It details financial terms (milestone payments, royalties) and strategic collaboration. This type of announcement, concerning the transfer of exclusive rights for development and commercialization, falls under corporate financing or strategic activity. Since it is not a standard regulatory filing (like 10-K or IR), nor a management change (MANG), dividend (DIV), or director dealing (DIRS), it best fits the 'Capital/Financing Update' category (CAP) as it involves a significant financial transaction and restructuring of asset rights, or potentially 'Regulatory Filings' (RNS) as a general corporate announcement. Given the focus on licensing and financial consideration, CAP is the most specific fit among the provided options for a major business deal that isn't M&A (TAR). The document is a formal press release announcing the deal, not a report itself, but it is a specific corporate action announcement, making CAP more appropriate than the general RNS fallback.
2016-08-17 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Classification · 100% confidence The document is titled 'MEDIVIR AB – DELÅRSRAPPORT JANUARI – JUNI 2016', which translates to 'Interim Report January – June 2016'. It contains comprehensive financial statements, including income statements, cash flow summaries, and management commentary for the specified period. It is a substantive financial report rather than an announcement or a certification, fitting the definition of an Interim/Quarterly Report. H1 2016
2016-08-17 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Classification · 100% confidence The document is titled 'MEDIVIR AB – INTERIM REPORT, JANUARY – JUNE 2016'. It contains comprehensive financial statements, including income statements, cash flow data, and detailed management analysis of the company's performance for the second quarter and the first six months of 2016. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). H1 2016
2016-08-17 English
Nya fas IIa interimdata för simeprevir i kombination med andra direktverkande antiviraler kommer att presenteras vid EASL AASLD’s specialkonferens
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing that interim data from a Phase IIa study involving their drug simeprevir will be presented at a medical conference (EASL/AASLD). It details the study's focus (HCV treatment), the presentation date, and includes standard boilerplate information about the company and regulatory disclosure. This type of announcement, which communicates specific, non-financial operational or clinical development news to the market, fits best under the general 'Regulatory Filings' category (RNS) as it is a formal public disclosure that doesn't align with specific financial reports (10-K, ER, IR) or corporate governance documents (DEF 14A, MANG). It is not a transcript (CT), an investor presentation (IP), or a formal audit report (AR). Given the nature of the announcement (clinical trial data presentation), RNS is the most appropriate catch-all for significant, non-standard regulatory disclosures.
2016-08-11 Swedish
New interim phase IIa data on simeprevir in combination with other DAAs will be presented at the upcoming EASL AASLD Special Conference
Regulatory Filings Classification · 95% confidence The document is a short press release from Medivir AB announcing that new clinical data regarding their drug simeprevir will be presented at an upcoming scientific conference (EASL AASLD Special Conference). It details the presentation title, date, and content (interim data on safety, pharmacokinetics, and efficacy). It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a formal regulatory filing like a proxy statement. Since it is an announcement about clinical trial data presentation, it functions as a general corporate update or news release. Given the options, it is best classified as a general Regulatory Filing (RNS) as it is a standard press release format used to disseminate material, non-financial corporate news that doesn't fit the other specific categories like DIV, DIRS, or CAP. The length is short, and it is an announcement, not the presentation itself.
2016-08-11 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.